Evidence Intelligence™
- ImpactScore™
- 77
- Positive
- EvidenceScore™
- 88
- Strong
- ConsistencyScore™
- 90
- consistent
Supporting studies: Based on 11 studies
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Once-weekly semaglutide improves glycemic control in Korean adults with T2D
Última actualización 5 de julio de 2026
Key finding
HbA1c decreased by 1.6% with semaglutide 0.5 mg.
This study evaluated the efficacy and safety of once-weekly semaglutide in Korean adults with type 2 diabetes, showing significant improvements in HbA1c and body weight.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
High Risk
Guarda este estudio en tu Evidence Tracker para encontrarlo facilmente cuando lo necesites.
Plain-language summary
What this paper says
A plain-language read of the study's main message and where it applies.
Study focus
This study evaluated the efficacy and safety of once-weekly semaglutide in Korean adults with type 2 diabetes, showing significant improvements in HbA1c and body weight.
Clinical relevance
These findings are significant as they suggest that semaglutide can be an effective treatment option for managing type 2 diabetes in Korean adults, potentially leading to better health outcomes. Achieving target HbA1c levels is crucial for reducing the risk of diabetes-related complications, making semaglutide a valuable addition to diabetes management strategies.
Keep in mind
Limited to Korean adults, affecting generalizability. Short duration may not capture long-term effects. Potential bias in self-reported outcomes.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Byung-Wan L, Young MC, Sin GK, et al. Efficacy and Safety of Once-Weekly Semaglutide in Korean Adults with Type 2 Diabetes: A Post Hoc Analysis. Diabetes Therapy. 2024;15(2):547-563. doi:10.1007/s13300-023-01515-0
Efectos Principales
HbA1c decreased by 1.6% with semaglutide 0.5 mg.
Body weight decreased by 4.8 kg with semaglutide 1.0 mg.
87.5% of participants achieved HbA1c <7.0% with semaglutide 1.0 mg.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Semaglutide, Sitagliptin and Body weight, Composite endpoint achievement, HbA1c.
This study contributes evidence to
Primary intervention
Semaglutide
Primary outcomes
- Body weight
- Composite endpoint achievement
- HbA1c
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
6
Evidence pairs
6
Relationships
4
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
4
Related topics
6
Evidence pairs
351
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 6 evidence relationships
- Includes primary outcome data
- Linked to 4 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
GLP-1 Receptor Agonists and Body Weight
Evidencia relacionada
Relación de evidencia
GLP-1 Receptor Agonists and HbA1c
Seguir evidencia
Relación de evidencia
DPP-4 Inhibitors and HbA1c
Seguir evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Composite endpoint achievement
Semaglutide → Composite endpoint achievement
Semaglutide → Composite endpoint achievement
Evidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- ImpactScore™
- 88
- Very Positive
- EvidenceScore™
- 87
- Strong
- ConsistencyScore™
- 83
- consistent
Supporting studies: Based on 12 studies
Add to Evidence TrackerEvidence Intelligence™
- ImpactScore™
- 75
- Positive
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
Add to Evidence TrackerComposite endpoint achievement
Sitagliptin → Composite endpoint achievement
Sitagliptin → Composite endpoint achievement
Evidence Intelligence™
- ImpactScore™
- 50
- Neutral
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- ImpactScore™
- 89
- Very Positive
- EvidenceScore™
- Strong
- Score 79 · Based on 4 studies
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 4 studies
Add to Evidence TrackerBuild your personal Evidence Workspace
Create a free account to save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Today's Activity
Your Evidence Workspace
Saved this study
Your free account becomes your personal diabetes evidence workspace.
Evidence Tracker
12 tracked topics
Saved Studies
48 studies
Research Notes
Coming Soon
Weekly Evidence Digest
Coming Soon
La Evidencia Sugiere
- 80% of participants achieved HbA1c <7.0% with semaglutide 0.5 mg.
- 42.9% achieved weight loss ≥5% with semaglutide 0.5 mg.
- 1.8% HbA1c reduction observed with semaglutide 1.0 mg.
A quién se aplica
- Korean adults aged 18-75 with type 2 diabetes.
- Individuals not achieving glycemic control with other treatments.
Tener en Cuenta
- Results may not apply to non-Korean populations.
- Further studies needed to assess long-term safety.
- Effectiveness may vary based on individual patient characteristics.
Entre Líneas
- Limited to Korean adults, affecting generalizability.
- Short duration may not capture long-term effects.
- Potential bias in self-reported outcomes.
Save this study
Keep this study in your Evidence Tracker so you can easily find it again whenever you need it.
Today's Activity
Your Evidence Workspace
Saved this study
Your free account becomes your personal diabetes evidence workspace.
Evidence Tracker
12 tracked topics
Saved Studies
48 studies
Research Notes
Coming Soon
Weekly Evidence Digest
Coming Soon
Already have an account?
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Body Weight, GLP-1 Receptor Agonists and HbA1c.
Relaciones de evidencia relacionadas
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Detailed evidenceGLP-1 Receptor Agonists → Body Weight
Medications
Evidence Intelligence™
- ImpactScore™
- 77
- Positive
- EvidenceScore™
- 88
- Strong
- ConsistencyScore™
- 90
- consistent
Supporting studies: Based on 11 studies
View evidenceMedications
Detailed evidenceGLP-1 Receptor Agonists → HbA1c
Medications
Evidence Intelligence™
- ImpactScore™
- 88
- Very Positive
- EvidenceScore™
- 87
- Strong
- ConsistencyScore™
- 83
- consistent
Supporting studies: Based on 12 studies
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
HbA1c Evidence Hub
All studies measuring HbA1c
12 studies
outcome_hubMeasures HbA1c as a key outcome.
Body Weight Evidence Hub
All studies measuring Body Weight
11 studies
outcome_hubMeasures Body Weight as a key outcome.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
11 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explora más en el archivo de evidencia
Jump to pre-filtered views in the evidence archive.
All studies on Semaglutide and Body weight
Intervention: SemaglutideOutcome: Body weight
11 results
All studies on Semaglutide and HbA1c
Intervention: SemaglutideOutcome: HbA1c
12 results
All studies on Semaglutide
Intervention: Semaglutide
11 results
All studies measuring Body weight
Outcome: Body weight
11 results
All studies measuring HbA1c
Outcome: HbA1c
12 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does GLP-1 Receptor Agonists affect body weight?
Strong Evidence
GLP-1 Receptor Agonists may improve Body Weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Strong | EvidenceScore™ 87.5 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 26 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists improve HbA1c?
Strong Evidence
GLP-1 Receptor Agonists appears to improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 87.5 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 26 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does DPP-4 Inhibitors improve HbA1c?
Strong Evidence
DPP-4 Inhibitors appears to improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 79.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 7 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does DPP-4 Inhibitors affect body weight?
Strong Evidence
DPP-4 Inhibitors may improve Body Weight.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is based on 4 supporting studies with generally consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, archive views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in archive
Open broader archive views for this relationship.
Related research
Read related research summaries.
Semaglutide may reduce cardiovascular events in non-diabetic patients.Newer diabetes drugs show stronger weight and blood sugar benefits in prediabetesOral semaglutide reduces cardiovascular events in type 2 diabetesHigher semaglutide doses improve glucose control in type 2 diabetesNovel Semaglutide Injection Shows Non-Inferior Glycemic Control
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.